logo
Giving mangosteen ‘queen treatment' to reverse declining yield

Giving mangosteen ‘queen treatment' to reverse declining yield

The Star4 days ago
Growing effort: Mardi is studying seedling growth, with trials on Mesta mangosteen seedlings.
PETALING JAYA: The Agriculture and Food Security Ministry is considering pairing Musang King durian and mangosteen as Malaysia's official 'king' and 'queen' of fruits, following concerns over the decline in mangosteen production in recent years.
Agriculture Department director-­general Datuk Nor Sam Alwi said mangosteen output fell from 23,297 tonnes in 2020 to 22,073 tonnes in 2023 due to a range of factors.
'Shifting rainfall patterns and rising temperatures disrupted flowering and fruit-setting, leading to inconsistent yields and lower fruit quality,' she said when contacted.
However, she noted that preliminary data for 2024 indicates a significant recovery, with production rising to 30,231 tonnes.
Nor Sam said movement restrictions and a shortage of foreign labour during the Covid-19 pandemic further hampered harvesting and orchard maintenance in 2020 and 2021.
The crop also became increasingly vulnerable to translucent flesh disorder and gamboge disorder, which are physiological issues affecting fruit quality.
'Mangosteen has a long juvenile phase, taking more than six years to reach full production.
'This discourages investment, especially when compared to faster-­yielding and more profitable crops like durian,' she added.
In a written reply to The Star, the Malaysian Agricultural Research and Development Insti­tute (Mardi) said it is actively conducting research and development (R&D) to improve mangosteen yields and address production challenges.
Among its key initiatives is the conservation of genetic resources. Mardi maintains a wide collection of tropical fruit varieties, including from the Garcinia genus, to which mangosteen belongs, in field genebanks across its research stations for future breeding programmes and cultivar improvements.
To boost productivity, Mardi has tested the application of paclobutrazol, followed by potassium nitrate or Bicomine, at its Sintok station in Kedah.
The treatment significantly improved flowering and fruiting compared to untreated trees.
To address labour shortages, Mardi is also researching manpower required to harvest mangosteens at various maturity stages.
This work supports the development of mechanical harvesting tools to reduce dependence on manual labour and enable commercial-­scale operations.
Mardi is also studying seedling growth, with trials on Mesta mangosteen seedlings using different growing media aim to improve early development and support stronger orchard establishment.
Although not mangosteen-­specific, Mardi's broader R&D in climate-resilient agriculture – applied to crops such as paddy, mango, pineapple and durian – is likely to benefit mangosteen cultivation as well.
Orchard owner Edmond Chow said growing mangosteen requires just as much time and cost as durian but offers far lower returns.
'It takes seven to 10 years for a mangosteen tree to bear fruit, just like durian. But while Musang King sells for RM30 to RM50 per kg, mangosteen only fetches RM8 to RM9.'
Kuala Lumpur Fruits Whole­salers' Association president Chin Nyuk Moy said Malaysia still imports mangosteens, mainly from Thailand and Indonesia, and occasionally from China.
'Local mangosteens are now hard to come by. Some orchards in Raub still grow the Japan variety, but the days when mangosteens appeared during durian season are mostly over,' she said.
'With low yields, short shelf life and limited demand, mangosteens remain pricey – with some imported ones costing RM15 to RM20 per kg,' she added.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Malaysia's healthcare travel industry eyes RM12 bil by 2030
Malaysia's healthcare travel industry eyes RM12 bil by 2030

Focus Malaysia

time20 hours ago

  • Focus Malaysia

Malaysia's healthcare travel industry eyes RM12 bil by 2030

MBSB Research recently hosted the Malaysia Healthcare Travel Council (MHTC) in a roundtable dialogue recently. While MHTC focuses on the private healthcare sector, various government ministries, are involved to ensure a cohesive and supportive ecosystem for medical tourism. This multi-agency cooperation is crucial for addressing the diverse needs of the industry, from healthcare standards to visa facilitation and economic planning. Since the decline in Covid-19 prevalence, Malaysia had seen a surge in medical travellers from the Asia-Pacific region seeking treatments. In 2024, the number of medical travellers reached 1.52 mil and revenue at RM2.72 bil. For 2025, MHTC is expecting revenue to climb up to RM3 bil, attributed by a robust demand for quality and affordable care. By 2030, MHTC aims to generate over RM12 bil in revenue, supported by continuous expansion of hospital capacity, targeted promotional efforts and implementation of integrated healthcare. Medical tourism in Malaysia is not just about hospital revenue. It creates a significant ripple effect across the economy. As foreign patients and their companions travel, they spend on various services beyond medical treatments, including accommodation, transportation, dining, and entertainment. This multiplier effect is a critical driver of growth for the hospitality, tourism, and food & beverage sectors. The revenue projected at RM12 bil by 2030 solely accounts for medical-related expenses and excludes the substantial spending on other associated services. This revenue, combined with an estimated economic multiplier of 4x, demonstrates the significant financial benefits of the industry. Every region in Malaysia contributed to medical tourism. In 2024, Central Region contributed 42% of the total revenue (RM886 mil) while Northern Region contributed 41%, Southern Region contributed 12% and the others (East Coast and East Malaysia) contributed 5%. Penang remains a major hub for medical tourism, serving up to 40% of the total volume of medical tourists. Its appeal is driven by its cultural affinity with Mainland Chinese and Indonesians, as well as its strategic proximity, which is supported by high flight frequency. Despite contributing the lowest revenue, East Coast had seen a gain in tourist volumes; likely due to the support from the state tourism and its proximity to Thailand. Meanwhile, Sabah and Sarawak saw high potential for growth, if state hospital brands are well promoted and accessibility by air and land are improved. Malaysia's competitive edge in the regional medical tourism market is its highly regulated healthcare environment. This offers a distinct advantage over competitors like Thailand and attracts patients seeking a safer and more structured treatment setting. Despite the first quarter typically not being a peak period, quarter one of 2025 already recorded a significant 8% increase in revenue (RM631 mil-682 mil) and a 7% rise in traveller volume (370,000-398,000). This indicates that Malaysia still retains an undulated potential and competitiveness in medical tourism. A key advantage for Malaysia is that foreign patients are charged the same rates as locals, which incentivizes them to spend more on other industries like tourism and hospitality. However, regional disparities remain a key challenge. While Penang is a major driver of medical tourism, largely due to key institutions like Island Hospital, East Malaysia struggles to attract medical tourists because of accessibility challenges, limited flight frequency, and less-known hospitals. 'Moving forward, we expect MHTC and other travel-related agencies and sectors (hospitality, consumer and aviation) to improve accessibility, as advocated by the government under the 13th Malaysia Plan,' said MBSB Research. —Aug 6, 2025 Main image: Senior Planet

US cancels mRNA vaccine contracts amid safety concerns
US cancels mRNA vaccine contracts amid safety concerns

The Sun

timea day ago

  • The Sun

US cancels mRNA vaccine contracts amid safety concerns

WASHINGTON: The US government has terminated 22 federal contracts for mRNA-based vaccines, raising questions about the safety and effectiveness of a technology widely credited with curbing the Covid-19 pandemic. The decision, announced by Health Secretary Robert F. Kennedy Jr., reflects growing skepticism within the administration regarding mRNA vaccines. 'We reviewed the science, listened to the experts, and acted,' Kennedy said in a statement. The Biomedical Advanced Research and Development Authority (BARDA) is ending investments in mRNA vaccines, citing insufficient protection against upper respiratory infections like Covid and flu. 'We're shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate,' he added. The move affects Moderna's mRNA bird flu vaccine, along with programs from Pfizer and Sanofi, totaling nearly $500 million in canceled projects. Some late-stage initiatives were spared to preserve taxpayer investments. 'HHS supports safe, effective vaccines for every American who wants them,' Kennedy emphasized. Since assuming office, Kennedy has reshaped US health policy, dismissing a panel of vaccine experts and replacing them with his own appointees. The new panel recently banned a vaccine preservative long deemed safe but criticized by anti-vaccine groups. Additionally, Kennedy has ordered a new study revisiting the debunked link between vaccines and autism. Unlike traditional vaccines that use weakened pathogens, mRNA vaccines deliver genetic instructions to cells, training the immune system to recognize and combat infections. Despite decades of development, mRNA technology gained prominence through Operation Warp Speed, a Trump-era initiative that fast-tracked Covid-19 vaccines. Pioneers Katalin Kariko and Drew Weissman won the 2023 Nobel Prize in Medicine for their contributions to mRNA vaccine development. The decision has sparked debate among scientists, with some questioning the administration's reliance on contested claims while others see it as a shift toward alternative vaccine approaches. - AFP

Pfizer reports strong Q2 revenue
Pfizer reports strong Q2 revenue

The Star

timea day ago

  • The Star

Pfizer reports strong Q2 revenue

NEW YORK, Aug. 5 (Xinhua) -- U.S. pharmaceutical company Pfizer announced its second-quarter earnings on Tuesday, reporting a 10 percent year over year operational growth. The financial results posted by the New York-headquartered company represent revenue of 14.7 billion U.S. dollars or 0.51 dollars of earnings per share. In an upward revision of its full-year guidance, Pfizer said it now expects adjusted earnings per share for 2025 to range between 2.90 dollars and 3.10 dollars, compared to its previous forecast of 2.80 dollars to 3.00 dollars. The company maintained its annual revenue projection of 61 billion to 64 billion dollars, reflecting confidence in its underlying business performance. "Our business is performing well and I'm pleased with the progress we achieved in the second quarter," Pfizer Chairman and CEO Albert Bourla said in a statement. Pfizer's strong performance came amid mounting policy pressures from the White House. U.S. President Donald Trump has recently sent letters to 17 pharmaceutical companies, including Pfizer, demanding that they cut prices on all existing medications for Medicaid patients to levels no higher than those in Europe. During Tuesday's earnings call, Bourla acknowledged that the company received the letter from the Trump administration. However, he declined to elaborate on the policy's specific impacts, although he emphasized that discussions with the administration have been "extremely productive." Pfizer's Q2 results were bolstered by rising sales in several key product categories. Its Vyndaqel line of cardiomyopathy treatments showed solid growth, and COVID-19-related products were major contributors.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store